nature medicine a r t i c l e s Astrocytes are the most abundant cell population in the central nervous system (CNS). They participate in diverse functions, including control of the blood-brain barrier (BBB), the regulation of metabolism, the modulation of neuronal transmission, and CNS development and repair [1] [2] [3] [4] [5] [6] [7] [8] [9] . Astrocytes also have important roles during CNS injury and disease, and are thought to participate in the pathogenesis of MS and in the EAE animal model of MS [10] [11] [12] . Astrocyte activity is affected by factors produced within and outside the CNS; therefore, the study of these factors may shed light on the regulation of astrocyte function in health and disease and identify new therapeutic approaches for neurological disorders.
a r t i c l e s
Astrocytes are the most abundant cell population in the central nervous system (CNS). They participate in diverse functions, including control of the blood-brain barrier (BBB), the regulation of metabolism, the modulation of neuronal transmission, and CNS development and repair [1] [2] [3] [4] [5] [6] [7] [8] [9] . Astrocytes also have important roles during CNS injury and disease, and are thought to participate in the pathogenesis of MS and in the EAE animal model of MS [10] [11] [12] . Astrocyte activity is affected by factors produced within and outside the CNS; therefore, the study of these factors may shed light on the regulation of astrocyte function in health and disease and identify new therapeutic approaches for neurological disorders.
The microbial flora and its products have been shown to control T cell-dependent inflammation through several mechanisms, including the conversion of precursors provided by the diet into immuneregulatory metabolites [13] [14] [15] . However, less is known about the effects of the diet and microbial products on the inflammatory response of resident cells in the CNS. Here we identify an IFN-I and AHR axis that integrates immunologic, metabolic and environmental cues to regulate astrocyte activity and CNS inflammation.
RESULTS

Astrocytes show a transcriptional response to IFN-Is in EAE
To study the regulation of astrocyte function in autoimmune CNS inflammation, we induced EAE in C57BL/6 mice by immunizing the mice with myelin oligodendrocyte glycoprotein 35-55 peptide (MOG ) in complete Freund's adjuvant (CFA) and analyzed mRNA expression in astrocytes by RNA sequencing (RNA-seq) ( Supplementary Fig. 1a,b) . We detected 17,964 expressed genes ( Fig. 1a) and found 1,869 transcripts that were differentially regulated in astrocytes from mice with EAE than in astrocytes from naive mice (Fig. 1b) . Although these transcripts were associated with different functional families, ingenuity pathway analysis and functional gene clustering revealed that most of the genes were linked to IFN-I signaling (Supplementary Table 1 ). Upregulation of genes associated with IFN-I signaling during EAE was validated in an independent set of astrocyte samples by qPCR (Fig. 1c) .
We also validated the upregulation of genes that were previously associated with EAE, including chemokine (C-C motif) ligand 2 (Ccl2), nitric oxide synthase 2, inducible (Nos2) and colony-stimulating factor 2 (granulocyte-macrophage) (Csf2) 4, 8, 11 ( Supplementary Fig. 1c ). After adjustment for the number of cells, astrocytes were a dominant source of Ccl2, Nos2 and Csf2 expression in the inflamed CNS ( Supplementary  Fig. 1d ,e). The expression of these genes in astrocytes was more strongly induced by immunization with MOG in CFA than with CFA alone, suggesting that it is mostly triggered by immune cell infiltration into the CNS (Supplementary Fig. 2 ).
IFN-I signaling in astrocytes limits CNS inflammation
IFN-Is are important regulators of inflammation in the context of infections, autoimmunity and other physiological processes [16] [17] [18] . To investigate the role of IFN-I signaling in astrocytes during EAE, we knocked down expression of interferon (alpha and beta) receptor 1 (Ifnar1) using a lentivirus-delivered shRNA (shIfnar1) expressed under the control of the glial fibrillary acidic protein (Gfap) promoter, which in this vector also controls the expression of green fluorescent protein (GFP) 11, 19 (Fig. 2a) . The lentivirus was administered intracerebroventricularily into the CNS 7 d and 15 d after EAE induction; a lentivirus carrying a nontargeting shRNA was used as a control (shControl). Ifnar1 silencing worsened EAE, as indicated by higher disease scores and failure to recover (Fig. 2a) .
As assessed by qPCR, Ifnar1 expression was efficiently knocked down in GFP + astrocytes sorted from shIfnar1-treated mice, but not in microglia (Fig. 2b) . Transcripts associated with the response to IFN-Is, such as Mx1, and other genes of the IFN-I signaling pathway (Stat1, Stat2 and Irf9) were downregulated in shIfnar1-treated astrocytes but not in microglia (Fig. 2b) . In agreement with the worsening of EAE, we detected upregulation of pro-inflammatory genes (Ifng, Il6, Nos2, Ccl2 and Il23a) in astrocytes from shIfnar1-treated mice (Fig. 2c) , by using custom-made NanoString nCounter arrays (Supplementary Table 2 ). Moreover, Ifnar1 knockdown reduced the expression of the gene encoding the immunomodulatory transcription factor aryl hydrocarbon receptor (Ahr) and of the AHR target gene Cyp1b1 in astrocytes (Fig. 2c,d ). Although Ifnar1 knockdown was restricted to astrocytes, it was also associated with the increased expression of genes encoding pro-inflammatory factors in microglia and LY6C1 hi monocytes (Fig. 2e,f and Supplementary Table 3 ), suggesting that IFN-I signaling modulates functional interactions between astrocytes and myeloid cells. Taken together, these data show that IFN-I signaling in astrocytes limits CNS inflammation and induces AHR expression.
IFN-Is induce AHR expression in astrocytes
AHR regulates inflammation through its effects on several components of the immune system 20, 21 . We first investigated whether Ahr expression is controlled by IFN-I signaling in astrocytes. Similarly to what has been previously reported for IFN-β (ref. 22) , expression of Ahr and its target gene Cyp1b1 was increased in astrocytes after induction of EAE (Fig. 3a) . In agreement with our in vivo findings, treatment with IFN-β upregulated Ahr expression in primary mouse astrocytes in culture in an IFNAR1-dependent manner (Fig. 3b) .
Astrocytes produce interleukin (IL)-27 (ref. 23) , and IL-27 is thought to contribute to the therapeutic effects of IFN-β in MS 24 . Although IL-27 upregulates Ahr expression in dendritic cells (DCs) and CD4 + type 1 regulatory T (Tr1) cells [25] [26] [27] , IFN-β treatment also upregulated Ahr expression in IL-27-receptor-deficient astrocytes, indicating that IFN-β induces Ahr expression independently of IL-27 ( Supplementary Fig. 3a) .
We then analyzed the direct regulation of Ahr expression by IFN-β. IFNAR1 activation triggers Janus kinase 1 (JAK1)-and tyrosine kinase 2 (TYK2)-dependent phosphorylation of signal transducer and activator of transcription 1 (STAT1), which dimerizes with phosphorylated STAT2 (ref. 17) . The STAT1-STAT2 heterodimer assembles with interferon regulatory factor 9 (IRF9) to form a trimolecular complex called IFN-stimulated gene factor 3 (ISGF3), which translocates to the nucleus and binds specific IFN-response elements (ISREs) to control the expression of interferon-stimulated genes (ISGs) (Fig. 3c) . In line with these findings, exposure of primary astrocyte cultures to IFN-β resulted in the phosphorylation of both STAT1 and STAT2, which peaked after 15 min (Fig. 3d) . Inhibition of ISGF3 assembly by treatment with trichostatin A or impairment of ISGF3 translocation to the nucleus by treatment with sodium fluoride (NaF) inhibited the upregulation of both of the ISGF3 target genes Mx1 and Ahr (Fig. 3e) .
A bioinformatic analysis of the Ahr promoter identified an ISRE that could be targeted by STAT1-STAT2-containing ISGF3 complexes that are formed in response to IFNAR1 activation, in addition to four STAT1-binding sites that could be recognized following STAT1 activation by other stimuli, such as IFN-γ (Fig. 3f) . In vitro activation of astrocytes by treatment with IFN-β resulted in the recruitment of STAT1 and STAT2 to the ISRE but not to the STAT1-binding sites in the Ahr promoter, as determined by chromatin immunoprecipitation (ChIP) assays (Fig. 3g) . These data suggest that STAT1 is recruited to the ISRE as part of an IFN-I-dependent ISGF3 complex containing STAT2. STAT1 and STAT2 were also recruited to the ISRE in the Ahr promoter in astrocytes after EAE induction in an IFNAR1-dependent manner (Fig. 3h) . Considering that upregulation of Ahr expression in astrocytes is dependent on IFNAR1 in EAE (Fig. 2c,d ), these data suggest that ISGF3 drives Ahr expression in astrocytes during CNS inflammation. Moreover, its increased recruitment to STAT1-binding sites following Ifnar1 knockdown suggests that IFN-Is limit the accessibility of STAT1 to those sites in vivo, probably through the formation of STAT1-STAT2 heterodimers and/or epigenetic mechanisms.
To further investigate the effects of IFN-β on AHR-dependent transcriptional regulation, we performed reporter assays using a construct in which an AHR-responsive promoter controls luciferase expression 28 . Exposure of HEK293 cells to IFN-β transactivated the AHR-responsive promoter (Fig. 3i) . This transactivation was mediated by AHR, as evidenced by inhibition of transactivation in the (n = 10 mice per group). Data are mean ± s.e.m. and representative of two independent experiments. **P < 0.01 by two-way analysis of variance (ANOVA). (b) qPCR analysis of the indicated genes in astrocytes expressing shControl or shIfnar1 (as identified by GFP expression at the peak of EAE in mice and isolated by FACS-sorting) (top) or in the entire CD11b + CD45 lo microglia population (bottom) (n = 4 mice per group). Data are representative of two independent experiments. (c) Fold change in mRNA expression of the indicated genes from sorted astrocytes from shIfnar1-and shControl-injected mice during peak disease, as determined by NanoString analysis (fold change in relative expression as determined by log 2 (shIfnar1/shControl)). Data are representative of two independent experiments of pooled astrocytes from n = 3 mice per group. Table 3 ) from sorted microglia (e) and LY6C1 hi pro-inflammatory monocytes (f). Data are ratio of count numbers of shIfnar1-expressing cells to those of shControl-expressing cells, and are representative of two independent experiments of pooled microglia and macrophages with n = 3 mice per group. Throughout, data are mean + s.e.m. *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not statistically significant; by Student's t-test (normalized to Irf9 levels in shControl-expressing microglia (b) or to Cyp1b1 levels in shIfnar1-expressing astrocytes (d)). . Data are mean + s.e.m. and are representative of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., not statistically significant; by Student's t-test (a (normalized to Ahr in naive mice)) or one-way ANOVA followed by Tukey's multiple-comparisons test (b (normalized to Ifnar1 levels in 'vehicle -IFN-β'), d,e (normalized to Mx1 levels in control), g (normalized to nonspecificantibody-and vehicle-treated control), h (normalized to nonspecific-antibody-treated WT cells), i (normalized to vehicle control)). npg a r t i c l e s presence of the AHR-specific antagonist CH-223191 (Fig. 3i) . Collectively, these findings suggest that ISGF3 that is assembled in astrocytes in response to IFN-β induces AHR-dependent transcriptional programs.
AHR expression in astrocytes limits CNS inflammation
To study the role of AHR expression in astrocytes on the regulation of inflammation in the CNS, we deleted Ahr in astrocytes by crossing mice with loxP-flanked ('floxed') alleles of Ahr (Ahr fl/fl ) to mice expressing Cre recombinase under the control of the Gfap promoter 29 . EAE was induced in Gfap-Cre + Ahr fl/fl (hereafter referred to as GFAP-AHR − ) and Gfap-Cre − Ahr fl/fl (control) mice, and disease course was monitored. EAE disease scores were worse in GFAP-AHR − mice, mostly characterized by failure of the mice to recover during the chronic phase of the disease ( Fig. 4a and Supplementary Table 4) . GFAP is also expressed outside the CNS, including in cells of the enteric nervous system 30 . Thus, it is possible that Gfap-driven Ahr deletion in these cells and not astrocytes is responsible for the worsening of EAE in GFAP-AHR − mice. To investigate the role of AHR in GFAP + astrocytes after EAE induction, we constructed a lentivirus in which an Ahr-targeting shRNA was expressed under the control of the Gfap promoter (shAhr-LV) and used it to knock down Ahr expression in GFAP + astrocytes. The administration of shAhR-LV to mice resulted in a significant worsening of EAE ( Supplementary  Fig. 3b,c) , suggesting that disease worsening in GFAP-AHR − mice results from AHR deficiency in GFAP + astrocytes and not in GFAP + cells outside the CNS.
AHR deficiency in astrocytes did not affect recall T cell responses in terms of proliferation or cytokine production in the periphery, or in the recruitment of effector and regulatory T cells to the CNS (Supplementary Fig. 3d-f) . However, expression of genes encoding chemokines (such as Ccl2, Ccl20 and Cxcl10), cytokines (such as Il6, Il12 and Il23) and pro-inflammatory markers (such as Vim, Nos2 and Csf2) was increased in Ahr-deficient astrocytes after induction of EAE (Fig. 4a, lower panel) . In agreement with the increased production of chemokines, Ahr deletion in astrocytes was associated with an increase in the number of CD11b + CD45 + LY6C1 hi CNS-infiltrating monocytes ( Fig. 4b and Supplementary Fig. 3f ). In addition, the expression of markers associated with inflammation and neurodegeneration were increased in microglia and monocytes from GFAP-AHR − mice ( Fig. 4c and Supplementary Table 3) .
To investigate the role of AHR in astrocytes, we studied wildtype (WT) and Ahr-deficient primary mouse astrocytes in culture. Expression of Ccl2, Csf2 and Nos2 was increased after activation of Ahr-deficient astrocytes with lipopolysaccharide (LPS) (Fig. 4c) . Astrocyte-produced factors have been linked to the recruitment of inflammatory monocytes to the CNS 31 . Supernatants from stimulated astrocytes promoted migration of CD11b + LY6C1 hi monocytes in Transwell assays, and this migration-promoting activity was increased in supernatants from Ahr-deficient astrocytes (Fig. 4d) . Blocking antibodies to CCL2, CSF2 (also called GM-CSF) and/or colony stimulating factor 1 (macrophage) (CSF-1; also called M-CSF) interfered with the migration of monocytes that was induced by astrocyte supernatants, suggesting that the increased expression of these molecules in Ahr-deficient astrocytes is responsible for their increased chemotactic activity (Fig. 4d) .
Astrocyte-produced factors modulate the polarization of microglia and monocytes, and they may also have direct neurotoxic effects 8, 11 . Co-culture of activated Ahr-deficient astrocytes with monocytes increased expression of pro-inflammatory markers (Il6, Il12, Il23a, Nos2 and Ccl2) and decreased the expression of Il10 in re-isolated monocytes (Fig. 4e) . Moreover, culture supernatants from Ahrdeficient astrocytes were more neurotoxic in vitro as compared to supernatants from WT astrocytes (Fig. 4e) . Taken together, these data show that AHR signaling in astrocytes controls transcriptional programs that regulate the recruitment of LY6C1 hi inflammatory monocytes to the CNS, the activation of microglia and monocytes, and astrocytic neurotoxic activities in EAE.
SOCS2 induced by AHR in astrocytes limits NF-kB activation
The transcription factor NF-κB regulates the response of astrocytes to activation and their potential pathogenic activities during CNS inflammation 32, 33 . To study the mechanisms used by AHR to regulate astrocyte function, we analyzed, using ChIP, the recruitment of NF-κB to the Ccl2, Csf2 and Nos2 promoters, because these genes have been linked to the recruitment of inflammatory monocytes to the CNS, the induction of neurotoxic activities in monocytes and microglia, and the direct neurotoxic activities in astrocytes 4, 8, 11 . Following in vitro activation, binding of NF-κB to the Ccl2, Csf2 and Nos2 promoters was increased in Ahr-deficient astrocytes, suggesting that AHR limits NF-κB activation in astrocytes (Fig. 4f) .
AHR has been reported to induce the expression of SOCS2 in B cells 34 , which interferes with NF-κB activation 35 . Activation of astrocytes in vitro with LPS or IFN-β induces the recruitment of AHR to target sites in the promoter of Socs2 and the AHR-dependent upregulation of Socs2 expression (Fig. 4g,h) . Activation of Ahr-or Socs2-deficient astrocytes with LPS in vitro resulted in increased NF-κB activation, supporting a role for SOCS2 in the suppression of astrocyte activation by AHR (Fig. 4i) . Expression of Ccl2, Csf2 and Nos2 was increased in in vitro-activated Socs2-deficient astrocytes (Fig. 4j) . Thus, these data suggest that AHR controls the pathogenic activities of astrocytes during EAE by limiting NF-κB activation in a SOCS2-dependent manner.
Astrocytic AHR mediates the suppressive effects of IFN-b IFN-β is a first-line therapy for individuals with MS, and it suppresses EAE 36, 37 . Previous studies in mice have focused mainly on the effects of peripherally administered IFN-β on T cells and monocytes because IFN-β does not cross the BBB 37 . To investigate the role of AHR on the effects of IFN-β on astrocytes in EAE, we administered IFN-β intranasally (i.n.), because this route of administration results in accumulation of IFN-β in the CNS 38 . In support of a CNS-restricted biodistribution of i.n. administered IFN-β, we detected the upregulation of Mx1 expression in astrocytes but not in splenic cells from WT mice (Fig. 5a) . Intranasal administration of IFN-β started 7 d after the induction of disease reduced EAE scores in WT but not GFAP-AHR − mice (Fig. 5b) . Conversely, the specific deletion of Ahr in microglia in Cx3cr1-CreERT2;Ahr fl/fl mice, in which Ahr is knocked out specifically in microglia 1 month after treatment with tamoxifen 39 , did not alter the effects of i.n. administered IFN-β (Supplementary Fig. 4a,b) . The expression of pro-inflammatory cytokines and activation markers in astrocytes was decreased in WT mice that were i.n. treated with IFN-β; this was not observed in astrocytes from the GFAP-AHR − mice (Fig. 5c, left) . Of note, the expression of the IFN-I-responsive gene Mx1 was not altered in GFAP-AHR − mice, as compared to control mice, indicating the co-existence of AHR-dependent and AHRindependent IFN-I-regulated genes. Il10 expression was upregulated in Ahr-deficient astrocytes (Fig. 5c, left) , suggesting that AHR does not drive Il10 expression in astrocytes as reported for T cells 25, 27, 40, 41 . The number of CNS-infiltrating monocytes (Fig. 5c, middle) the expression of pro-inflammatory molecules (Fig. 5c, right) were decreased in WT but not GFAP-AHR − mice after intranasal treatment with IFN-β. Hence, IFN-β signaling in astrocytes limits CNS inflammation in an AHR-dependent manner.
Dietary tryptophan limits CNS inflammation via AHR
The activity of AHR is regulated by small molecules, some of which are provided by diet and the commensal flora 20 . The AHR-dependent anti-inflammatory effects of IFN-β suggest that dietary and microbial AHR ligands might regulate IFN-I signaling in astrocytes, as well as inflammation in the CNS. Tryptophan (Trp) is an essential amino acid provided by the diet that is metabolized into several AHR ligands 20 . To study the AHR-dependent effects of the diet on the regulation of CNS inflammation by astrocytes, we induced EAE in WT and GFAP-AHR − mice and, starting on day 22, fed the mice a tryptophan-depleted diet (TDD) or TDD supplemented with Trp (TDD + Trp), as described 42 . Lack of dietary Trp worsened EAE scores (Supplementary Fig. 5a ) without affecting the levels of Trp or those of its catabolites serotonin and kynurenic acid in the CNS (Supplementary Fig. 5b ). The worsening of EAE scores could be reverted by Trp supplementation in control but not GFAP-AHR − mice (Fig. 5d) , suggesting that Trp-derived ligands of AHR function through astrocytes. Dietary Trp deficiency was associated with increased Ccl2 and Nos2 expression in astrocytes, which could not be reverted by Trp supplementation in GFAP-AHR − mice (Fig. 5e) . Trp-derived AHR agonists are generated through complex biochemical pathways catalyzed by commensal and host enzymes [42] [43] [44] . Indeed, ampicillin (Amp)-sensitive, vancomycin (Vanco)-resistant bacteria generate AHR agonists from dietary tryptophan 44 . Thus, we tested the effects of oral antibiotic administration on WT mice with late-stage EAE and found that treatment with Amp but not Vanco interfered with disease recovery (Fig. 5f) .
Bacterial tryptophanase (TnAse) catalyzes the conversion of dietary Trp to indole, which is used in the liver as a precursor for the synthesis of the AHR agonist indoxyl-3-sulfate (I3S) (refs. 43,45) . I3S is undetectable in germ-free mice, indicating that its generation is dependent on the commensal flora 43 . Indeed, Amp administration decreased urinary I3S levels (Fig. 5g) . Moreover, peripherally administered I3S crosses the BBB and activates AHRs in astrocytes ( Supplementary  Fig. 5c ). Collectively, these data suggest that I3S produced by Ampsensitive commensal bacteria participates in the regulation of astrocyte activity by AHR.
Intraperitoneal administration of I3S or supplementation of the diet with indole reduced EAE disease scores in Amp-treated mice (Fig. 5h) and increased I3S levels (Fig. 5g) Fig. 5g and Supplementary Fig. 5e,f) . Similar results were obtained when recombinant TnAse was administered by gavage to Amp-treated mice ( Fig. 5h and Supplementary Fig. 5e,f) .
TnAse-independent enzymatic reactions in commensal bacteria can also result in the synthesis of AHR agonists other than I3S, such as indole-3-propionic acid (IPA) and indole-3-aldehyde (IAld) 44 . A diet supplemented with IPA or IAld also reduced EAE scores in Amp-treated mice, while reducing Ccl2 and Nos2 expression in astrocytes (Fig. 5g,i) . Dietary supplementation with IPA or IAld, however, did not restore peripheral I3S concentrations (Fig. 5g) .
Lactobacillus reuteri has been described to participate in the transformation of dietary Trp into AHR agonists 44 . Notably, treatment with Amp but not Vanco was associated with a reduction in L. reuteri 16S Table 3 ) from sorted CD11b + CD45 lo microglia and CD11b + LY6C1 hi monocytes (representative out of two independent experiments of pooled microglia and macrophages of n = 3 mice per group; Student's t-test) (left) and RNA expression of indicated genes in astrocytes sorted from WT and GFAP-AHR − mice at peak of disease (n = 3 pooled samples consisting of two mice each; data are mean + s.e.m.; P values were derived by Student's t-test, normalized to Ccl2 levels in control astrocytes) (right). (d) Left, migration assays with supernatants of LPS-or vehicle-stimulated WT or GFAP-AHR − astrocytes, using CD11b + LY6C1 hi WT monocytes as migrating cells (n = 3 biological replicates; data are mean + s.e.m. and are representative of three independent experiments). **P < 0.01; n.s., not significant; by one-way ANOVA with Tukey's multiple-comparisons test. Right, migration assays using the indicated blocking antibodies or Il27ra −/− macrophages (n = 3 biological replicates; data are mean + s.e.m. and are representative of three independent experiments). P values were derived by one-way ANOVA within treatment groups and Tukey's multiple-comparisons test. KO, Ahr-deficient astrocytes. (e) Left, qPCR analysis for expression of the indicated genes from sorted CD11b + LY6C1 hi monocytes that were co-cultured with activated control or GFAP-AHR − astrocytes and re-isolated (n = 3 biological replicates; data are mean + s.e.m. and are representative of two independent experiments). P values were derived by Student's t-test (normalized to Ccl2 in controls in c). Right, neurotoxicity assay with supernatants from control or GFAP-AHR − astrocytes after treatment with LPS or vehicle (n = 3 biological replicates; data are mean + s.e.m. and are representative of two independent experiments). P values were derived by one-way ANOVA with Tukey's multiple-comparisons test. (f) ChIP analysis for binding of NF-κB (p65) to the promoters of Ccl2 (left), Csf2 (middle) and Nos2 (right) in control or GFAP-AHR − astrocytes after activation with LPS. (n = 3 biological replicates; data are mean + s.e.m. and are representative of two independent experiments). P values were derived by one-way ANOVA with Tukey's multiple comparisons test (normalized to signal at Ccl2 promoter from isotype (rIgG)-treated control cells). (g) Schematic of predicted AHR-binding sites (XREs) in the Socs2 promoter (top) and ChIP analysis for AHR binding to the Socs2 promoter in WT astrocytes after stimulation with the indicated conditions (bottom) (n = 3 biological replicates; data are mean + s.e.m. and are representative of two independent experiments). P values were derived by one-way ANOVA with Tukey's multiple-comparisons test (normalized to signal at Ccl2 promoter from rIgG-treated control cells). (h) Relative expression of Socs2 in WT or GFAP-AHR − astrocytes after stimulation with LPS. Data are mean + s.e.m. and are representative of two independent experiments. P values derived by one-way ANOVA with Tukey's multiple comparisons test (normalized to vehicle-treated control astrocytes). (i) Representative western blot analysis for NF-κB (p65) (left) and quantification of the ratio of nuclear to cytoplasmic fraction (right) of WT, GFAP-AHR − , and Socs2 −/− astrocytes stimulated as indicated. Data are mean + s.e.m. and are representative of three independent experiments. P values were derived by one-way ANOVA with Tukey's multiple-comparisons test. (j) qPCR analysis for the expression levels of Ccl2 (left), Csf2 (middle) and Nos2 (right) in control and Socs2 −/− astrocytes after stimulation with LPS. Data are mean + s.e.m. and are representative of two independent experiments. P values were derived by Student's t-test (normalized to Ccl2 levels in control cells). Throughout, *P < 0.05, **P < 0.01, ***P < 0.001; n.s., not statistically significant. npg a r t i c l e s 5 9 2 VOLUME 22 | NUMBER 6 | JUNE 2016 nature medicine rDNA levels in the feces of treated mice (Fig. 5j) . Taken together, these data suggest that L. reuteri and other Amp-sensitive, Vancoresistant commensal bacteria catalyze the conversion of dietary Trp into AHR agonists, which modulate astrocyte function in EAE, via TnAse-dependent and TnAse-independent pathways. without MS. Expression of MX1 and the IFN-I pathway genes STAT1, STAT2 and IRF9 was upregulated in brain samples from individuals with MS (Fig. 6a) . AHR expression was also upregulated in MS lesions (Fig. 6b) . In brain samples with MS lesions, phospho-STAT1, MX1 and AHR colocalized with GFAP + astrocytes in active and chronic MS lesions, as assessed by immunofluorescence (Supplementary Fig. 6 ), suggesting that IFN-I signaling promotes AHR expression in human astrocytes. Incubation of human fetal astrocytes in vitro with IFN-β upregulated the expression of AHR (Fig. 6c) . Activation of AHR by I3S decreased the expression of the pro-inflammatory-factor-encoding genes NOS2, TNF, IL6 and CCL2 in human astrocytes (Fig. 6d) . In co-staining studies, however, we detected the coexpression of AHR with CCL2 and inducible nitric oxide synthase (iNOS) in GFAP + cells (Fig. 6e and Supplementary Fig. 7) , suggesting that although AHR expression is induced by IFN-I signaling in individuals with MS, the AHR-dependent regulation of astrocyte function may be impaired in MS.
IFN-I-AHR signaling modulates human astrocyte activation
Expression of the AHR transcriptional target CYP1B1 is decreased in MS lesions and NAWM (Fig. 6f) . By using an AHR-responsive reporter to quantify AHR agonistic activity in sera from healthy control individuals and those with MS, we detected decreased AHR agonistic activity in sera from individuals with MS, as compared that in sera from controls (Fig. 6g) . Moreover, by using a metabolomics approach we detected decreased levels of Trp-derived AHRactivating molecules and related metabolites in sera from individuals with MS (Fig. 6h) . Taken together, these data support a role for the IFN-β-AHR axis in the regulation of human astrocytes and suggest that deficits in AHR agonists provided by metabolism, diet, the commensal flora or the environment may contribute to the pathogenesis of MS.
DISCUSSION
Here we describe a novel IFN-I-AHR axis that limits pathogenic astrocyte functions in MS and, potentially, other neurologic disorders. Beneficial and deleterious effects have been assigned to IFN-β in CNS inflammation. Peripheral IFN-β administration is a first-line diseasemodifying therapy for individuals with MS, and it is thought to act through its effects on dendritic cells (DCs), B cells and T cells 24, 37 . IFN-β, however, boosts the production of pathogenic antibodies and exacerbates immunopathology in neuromyelitis optica 46 . These opposing effects of IFN-β on CNS inflammation in MS and neuromyelitis optica highlight the need to study its cell-specific effects on CNS immunopathology.
Peripherally administered IFN-β does not cross the BBB, but substantial amounts of IFN-β are produced by astrocytes, microglia and CNS-infiltrating plasmacytoid DCs during EAE 47 . Microglia, infiltrating monocytes and neurons are cell populations that are directly targeted by IFN-β to arrest CNS inflammation and neurodegeneration 22, 48, 49 . We found substantial anti-inflammatory and neurodegeneration-arresting effects of IFNAR1 signaling in astrocytes that were mediated by AHR-driven transcriptional programs. Thus, our data support targeting IFNAR1 signaling within the CNS for the therapeutic control of inflammation and astrocyte-driven neurodegeneration. The translational value of IFNAR1 activation in astrocytes, however, should be evaluated in the context of the deleterious effects of excessive IFN-I signaling in the CNS 50 .
The study of AHR signaling in EAE has been focused on its role in the regulation of effector and regulatory T cells, either directly or through the modulation of DC function 27, 40, 41, [51] [52] [53] . AHR agonists with physiologically relevant and important immunomodulatory activities are provided by environmental sources and also by cellular metabolism 54, 55 . Together with recent reports of decreased levels of . P values were derived by one-way ANOVA followed by Tukey's multiple-comparisons test (relative to 'TDD + Trp'). Throughout, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., not statistically significant. npg a r t i c l e s AHR agonists in inflammatory bowel disease 56 , our data suggest that imbalances in the uptake, production and/or degradation of AHR agonists may contribute to the pathogenesis of MS and other immunemediated diseases, establishing a new link between the environment, metabolism and inflammation.
Environmental factors are known to contribute to the development of MS, but limited information is available about the identity of most of those factors and their mechanisms of action. Besides cellular metabolism, the diet and the commensal flora are abundant physiological sources of AHR agonists 20 . Depending on the experimental model, pro-and anti-inflammatory effects of the commensal flora have been recently reported 14, 15, [57] [58] [59] , highlighting the need to identify the molecular mechanisms by which the commensal flora regulates the immune response. In this context, our work contributes to the understanding of the anti-inflammatory effects of AHR agonists that are generated from dietary Trp by TnAse-dependent and TnAse-independent pathways in commensal bacteria 44 . Moreover, our results identify a molecular pathway through which the diet, in cooperation with the commensal flora, modulates the activity of CNS-resident cells and neuroinflammation. In addition, the regulation of Ahr expression by IFN-β suggests that the microbiome may affect not only the development of CNS autoimmunity but also its response to disease-modifying therapies 60 . Thus, the study of the metabolic and environmental factors that regulate astrocyte activity may shed light on CNS physiology, identify mechanisms of disease pathogenesis and drive the development of more efficacious therapeutic interventions for MS and other neurologic diseases. . Throughout, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., not statistically significant.
as indicated. In some experiments, transfected cells were exposed to 500 IU/ml of mIFN-β (Bio X cell) or AHR inhibitor CH223191 (Sigma). For the measurement of AHR ligands in human serum, 15,000 HEK293 cells were plated in 96-well plates 24 h before transfection with pGud-Luc and pTK-Renilla. After 24 h transfected cells were incubated with DMEM supplemented with 10% of patient serum. Luciferase activity was analyzed 24 h later using Dual Luciferase Reporter System (Promega) and normalized to Renilla luciferase activity.
In vitro knockdown with shRNA. Ifnar1 expression was knocked down in mouse primary astrocytes in culture using a lentivirus vector carrying an Ifnar1-targeting shRNA (TRCN0000374694); a lentivirus carrying a nontargeting sequence was used as a control (TRCN0000018782) (Sigma). Astrocytes were incubated with lentiviruses and 8 µg/ml polybrene (both from Sigma-Aldrich) for 24 h and thereafter incubated with mIFN-β (Bio-X-cell) or vehicle. GFP + astrocytes were sorted, and gene knockdown was verified by qPCR. Transduction efficiency, as determined by GFP expression in transduced astrocytes, was around 20% (data not shown).
In vivo astrocyte-specific knockdown with shRNA lentivirus. shRNA sequences against Ifnar1 or Ahr, or a nontargeting control shRNA, was cloned into the pLenti-Gfap-eGFP-mir30-shAct1 vector 19 backbone by replacement of the shAct1 with the above-mentioned in vitro-validated shRNA sequence against Ifnar1 (5′-CCGGGAATGAGGTTGATCCGTTTA TCTCGAGATAA ACGGATCAACCTCATTCTTTTTG-3′) or Ahr (5′-CCGG CATCGACATA ACGGACGAAATCTCGAGATTTCGTCCGTTATGTCGATGTTTTTG-3′) as previously described 11 . Lentivirus particles were generated by transfecting HEK293FT cells (Invitrogen) the newly generated pLenti-Gfap-eGFP -mir30-shRNA vectors and the ViraPower Packaging mix (helper plasmids pLP1, pLP2, pLP/VSV-G; Invitrogen). Supernatants were collected, filtered through a 0.45-µm PVDF filter and concentrated overnight with the Lenti-X concentrator kit (Clontech). The viral titer was determined using the Lenti-X qRT-PCR titration kit (Clontech). For in vivo knockdown, immunized mice were anesthetized at the indicated time points, positioned in a Kopf Stereotaxic Alignment System and injected with 10 7 IU of shIfnar1 or shControl virus using a Hamilton syringe 0.44 mm posterior to the bregma, 1.0 mm lateral to it and 2.2 mm below the skull surface. The injection system was retracted slowly and skin incisions were closed carefully by surgical sutures. Mice were allowed to awaken in a specific cage, prewarmed by red light, and were checked three times daily thereafter.
